Genticel

company

About

Gentiel develops therapeutic vaccines for the prevention of cervical cancer in HPV infected women.

  • 11 - 50

Details

Last Funding Type
Series D
Last Funding Money Raised
€18.20M
Industries
Biotechnology,Medical Device,Therapeutics
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active

Genticel is a French clinical stage biotechnology company founded by Benedikt Timmerman in 2001 and focused on the development of innovative immunotherapies designed to treat virus infections and virus-induced diseases. Genticel aims to become a leader in immunotherapy in multiple indications, starting with HPV and HPV induced diseases such as cervical cancer.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€18.20M $17.70M
Genticel has raised a total of €18.20M $17.70M in funding over 2 rounds. Their latest funding was raised on Apr 24, 2013 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 24, 2013 Series D €18.20M 1 Detail
Apr 5, 2010 Series C $17.70M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Genticel is funded by 1 investors. InnoBio Fund are the most recent investors.
Investor Name Lead Investor Funding Round
InnoBio Fund Series D